Welcome to FibroGenesis

FibroGenesis is undertaking an accelerated preclinical program to find a cure for COVID-19 Acute Respiratory Distress Syndrome (ARDS) using its advanced fibroblast cell therapy.

Multi-Pronged Attack on COVID-19:

FibroMune™ and PneumoBlast™

We are developing two products for treatment of COVID-19.  The first, FibroMune™, is comprised of conditioned media from activated fibroblasts, which induces interferon beta production when administered.  FibroMune™ is being developed to activate innate immunity in order to prevent virus propagation.  PneumoBlast™ is comprised of proprietary “universal donor” fibroblasts for the treatment of acute respiratory distress syndrome (ARDS), which is the main cause of COVID-19 mortality.  PneumoBlast™ reduces pulmonary pathology in mouse models of ARDS as well as protects/regenerates type II pulmonary epithelial cells.  We are seeking to conduct experiments in animal models of SARS-Cov-2 and toxicity evaluation to support FDA Investigational New Drug (IND) filing to enable clinical trials.


FibroGenesis, is a regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts. Currently, FibroGenesis holds 192 U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.

One area of focus is Degenerative Disc Disease.  Chronic Lower Back Pain afflicts an estimated 33 million people annually in the U.S. Over 7 million of those people suffer from Degenerative Disc Disease. Aging baby boomers may double those numbers in the next two decades. At FibroGenesis, we are the clinical stage world leader in patented fibroblast cell therapy to treat Degenerative Disc Disease.


Back pain is strongly associated with degeneration of the intervertebral disc. Disc degeneration, although in many cases asymptomatic, is also associated with sciatica and disc herniation or prolapse. It alters disc height and the mechanics of the rest of the spinal column, adversely affecting the behavior of other spinal structures such as muscles and ligaments. In the long term, it can lead to spinal stenosis, a major cause of pain and disability in the elderly. Degenerated disc incidence is rising with current demographic changes and an increased aged population.

Recent Developments

July 1, 2020

FibroGenesis Identifies Mechanism Responsible for Blocking COVID-19 Lung Inflammation  Read More

May 21, 2020

FibroGenesis Announces COVID-19 Breakthrough  Read More


April 21, 2020

FibroGenesis Files Its Landmark 200th Patent  Read More


April 1, 2020

FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS  Read More


March 10, 2020

FibroGenesis Files Patent to Treat Coronavirus (COVID-19) Acute Respiratory Distress Syndrome (ARDS)  Read More


February 3, 2020

FibroGenesis to Present at LSX World Congress  Read More


January 28, 2020

SpinalCyte Changes Name To FibroGenesis  Read More


December 12, 2019

SpinalCyte CEO, Pete O'Heeron named to 30 Best CEOs of 2020 List

See List Here

Read Interview Here

Read Press Release Here

December 11, 2019

SpinalCyte Announces New Australian Patent 

Read More


October 23, 2019

CEO/CFO Magazine Interviews SpinalCyte CEO,

Pete O'Heeron  Read More

October 21, 2019

SpinalCyte to Present at BIO Investor Forum  

Read More


October 15, 2019

SpinalCyte Announces New Japanese Patent 

Read More


September 19, 2019

SpinalCyte Announces New International Patent 

Read More


June 5, 2019

SpinalCyte to Present at Boao Forum in Qingdao, China  Read More

May 15, 2019

SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology  Read More

March 28, 2019

SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting  Read More


March 18, 2019

SpinalCyte to Present at China Focus @ Europe Vienna, Austria  Read More


March 11, 2019

SpinalCyte Announces Two New Patents  Read More


February 4, 2019

SpinalCyte to Present at the 2019 BIO CEO & Investor Conference  Read More


January 8, 2019

SpinalCyte Announces New International Patent  

Read More

News from Twitter


 Copyright © 2020 FibroGenesis. All rights reserved.